1.What is hepatic artery chemoembolization (TACE)? It is a kind of interventional treatment for hepatocellular carcinoma. It usually refers to puncturing the femoral artery at the root of the patient’s thigh, inserting a fine catheter into it and sending the catheter to the tumor site in the liver through the fluoroscopic guidance of digital subtraction angiography (DSA), and the doctor injects anti-cancer drugs and embolic agents into the tumor artery in the liver through the catheter. TACE can not only kill tumor cells directly, but also block the blood supply to the tumor, so that the tumor can be starved to death without nutrition, which is currently the first choice of treatment for middle and late stage liver cancer at home and abroad. 2.What patients are suitable for interventional treatment? Patients who are suitable for interventional treatment are: (1) Patients with middle and late stage primary liver cancer who cannot be surgically resected; (2) Patients who can be surgically resected but cannot or do not want to undergo surgery due to other reasons (such as advanced age, severe cirrhosis, etc.). (3) small hepatocellular carcinoma, but not suitable for or unwilling to undergo surgery, local radiofrequency or microwave ablation treatment; 3. What are the main roles of liver cancer interventional therapy? (1) treating middle and advanced hepatocellular carcinoma that cannot be surgically resected; (2) applying interventional therapy before open liver tumor resection can reduce the tumor volume, which is conducive to second-stage surgical resection and can clarify the number of lesions at the same time; (3) controlling local pain and bleeding as well as embolizing arteriovenous impotence; (4) for some patients with large tumors and high chance of recurrence after surgery, postoperative interventions can be done about 1 month after surgery to (4) Some patients have a high chance of recurrence due to large tumors and postoperative interventions can be done about 1 month after surgery to kill possible residual active lesions and reduce the chance of recurrence. 4.What conditions are not suitable for intervention? Patients with severe heart, brain, lung and other important organ diseases, liver function grade C or PS score greater than or equal to 3 are not suitable for interventional treatment. 5.Can we intervene again after relapse? After TACE treatment, the lesion is stable and there is no clear active lesion, regular review is sufficient. If there is a relapse, or if there is residual activity in the lesion after treatment, or if the lesion has progressed, TACE treatment should be repeated, with an interval of 4-6 weeks between TACE treatments, or the treatment interval can be extended according to the actual situation.